88. Biologics in autoimmune and kidney disease, Marshall Fordyce, CEO and Founder, Vera Therapeutics
Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments. Before founding Vera, Fordyce was the fo...
2 Helmi 202220min
87. Patient-centric Duchenne gene therapy, Joel Schneider, COO, Solid Biosciences
Dr. Schneider is the Chief Operating Officer for Solid Biosciences, responsible for overseeing corporate and technical operations, quality, patient advocacy, communications, corporate strategy, and hu...
26 Tammi 202234min
86. Resilient to the core, Trish Hurter, CEO, Jess Ballinger, President & COO, Lyndra Therapeutics
Patricia (Trish) Hurter, Dr. Patricia Hurter is CEO of Lyndra Therapeutics. Prior to Lyndra, Dr. Hurter was Senior Vice President of Pharmaceutical and Preclinical Sciences at Vertex Pharmaceuticals,...
19 Tammi 202231min
85. Genomic testing for precision oncology, Shawn Leland, Founder and CEO, Elevation Oncology
Shawn M. Leland is the Founder and Chief Executive Officer of Elevation Oncology overseeing all day-to-day operations. Shawn brings over a decade of experience in medical affairs and business developm...
12 Tammi 202225min
84. Leadership insights, Paul Biondi, President, Pioneering Medicines,Flagship Pioneering initiative
Paul Biondi, Executive Partner, Flagship Pioneering and President, Pioneering Medicines Paul joined Flagship Pioneering in 2019 as Executive Partner, Flagship Pioneering and President, Pioneering Med...
5 Tammi 202241min
83. Season 2 Wrap Up, Rahul Chaturvedi and Alok Tayi
Thank you for your support for Season 2! We reflect and look forward to Season 3 on this episode! Learn more about our co-hosts below! Alok Tayi, PhD is the Co-founder and CEO of Vibe Bio. Vibe is a ...
15 Joulu 20216min
82. RNA therapeutics for neurological indications, Barry Ticho, CMO, Stoke Therapeutics
As Chief Medical Officer Dr. Ticho is responsible for Stoke’s efforts to develop first-in-class RNA based disease-modifying medicines to treat severe genetic diseases. He is also co-founder and former...
8 Joulu 202127min
81. Innovations for narcolepsy, Greg Divis, CEO, Avadel Pharmaceuticals
Gregory J. Divis serves as Avadel’s Chief Executive Officer and a member of Avadel’s Board of Directors. Greg was appointed CEO in June of 2019, after previously serving in several leadership roles wi...
1 Joulu 202124min
